Dianthus Therapeutics, Inc. Email Format
Biotechnology ResearchNew York, United States51-200 Employees
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing new therapies for severe autoimmune and inflammatory diseases. Based in New York City and Waltham, Massachusetts, it brings together experienced leadership from biotech and pharma to advance treatment options for these conditions. A recent development is that the company has secured exclusive global rights to research, develop, manufacture, and commercialize LBL-047 outside Greater China, where the asset is known as DNTH212, to support its broader development. The DNTH212 program is being developed for Sjögren's syndrome.